<DOC>
	<DOCNO>NCT00993096</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial evaluate pharmacodynamic dose-response relationship NN5401 ( insulin degludec/insulin aspart ) three therapeutically relevant dos subject type 1 diabetes . The trial design four period , incomplete block cross-over trial trial participant randomise treatment sequence subject receive two match dose level NN5401 biphasic insulin aspart , respectively .</brief_summary>
	<brief_title>Investigation Response Relationship NN5401 Type 1 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) least 12 month Body mass index 18.028.0 kg/m^2 ( inclusive ) Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoke 5 cigarette equivalent per day ) Supine blood pressure screening ( rest 5 min ) outside range 90140 mmHg systolic 5090 mmHg diastolic Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>